Coverleaf experience

What more than 7,000 patient journeys taught us about medical cannabis

Experience cannot promise a medical outcome. It can help recognize the questions, obstacles and decisions that make a pathway clearer and safer.

By the Coverleaf editorial teamEditorial review: David Selema, founder and medical cannabis industry expertPublished Editorial policy

Coverleaf has supported patients since 2017. More than 7,000 people have gone through our assessment and support pathway. This volume is not a clinical trial and does not prove that a treatment works for a given condition. It has taught us how to structure decisions and follow-up more clearly.

1. A good assessment starts before products

The most useful questions first concern the goal, treatments already tried, current medications, driving, work and precautions. The product comes later. Authorization is never automatic: the practitioner decides whether medical cannabis is appropriate.

2. The most potent product is rarely the best starting point

Many new patients first compare THC percentages. In practice, a high concentration can complicate titration and increase adverse effects. Ratio, milligrams per dose, route and the ability to repeat the same dose often matter more.

3. Changing one variable helps explain the response

When someone changes the product, dose, time and format together, it becomes difficult to know what caused a difference. A simple journal—dose, time, target, function and adverse effects—makes follow-up far more useful.

4. The format has to fit daily life

An oil can be easy to measure but too slow for an occasional need. An inhaled format acts faster but carries respiratory and intoxication risks. The right choice accounts for onset, duration, lifestyle and individual precautions.

5. Seller availability is part of the plan

A theoretically ideal product is not helpful when it is constantly out of stock. We consider federal licensing, catalogue stability, available concentrations, total cost and the ability to handle VAC, CNESST or insurance billing when the program authorizes it.

6. Patients need explanations after authorization

Receiving a medical document does not automatically answer questions about registration, ordering, labels, starting or adverse effects. Support after the clinical decision reduces confusion and helps patients return to the practitioner with more precise observations.

7. Administrative coverage can be as complex as treatment

For Veterans and injured workers, forms, registration with a medical seller and billing can become barriers. Start-to-finish support helps organize the file, but VAC, CNESST or the insurer always keeps the final decision.

What experience cannot promise

We cannot guarantee authorization, coverage or a clinical outcome. Accumulated observations help us ask better questions, explain options more clearly and recognize tolerance, availability or administration problems earlier.

General information for adults of legal age. This content describes Coverleaf's operational experience, not the results of a clinical study. Do not change treatment without your health professional. In an emergency, call 911.
Frequently asked
Did all 7,000 patients receive an authorization?
No. An assessment never guarantees authorization. The decision belongs to the practitioner based on the individual situation.
Does Coverleaf recommend only one seller?
No. The choice depends on the medical document, desired products, availability, cost and coverage program.
Why follow up after starting?
Follow-up reviews tolerance, adverse effects, format and how the plan fits into daily life.
Go further

Ready to take the first step?

A licensed practitioner assesses your situation online, everywhere in Quebec — no referral, no travel.

Talk to a practitioner

Submit your request online today. The decision always rests with the practitioner after assessment.

General information, not medical advice.